ATEC stock forecast, quote, news & analysis
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma... Show more
Why Is Alphatec Holdings (ATEC) Stock Down -30.55% Today?
Key Takeaways
- ATEC shares plunged 30.55% to close at $7.11 from the previous close of $10.23.
- Primary catalyst: Q1 2026 earnings miss with revenue of $192 million versus expectations of $197.5 million, driven by weakness in EOS imaging sales.
- EPS of -$0.22 missed consensus of -$0.01; company lowered full-year EOS revenue guidance to $77 million while maintaining surgical revenue outlook at $805 million.
- Trading volume spiked to over 14 million shares, well above the average of 2.66 million, indicating heavy selling pressure.
- Move diverged sharply from broader market, with Nasdaq up over 1% and medical devices ETF (IHI) down only 0.28%.
- Traders watching EOS business recovery, Q2 execution, and surgeon adoption metrics ahead of next earnings in late July.
Opening Summary
Alphatec Holdings (ATEC), a medical technology company specializing in spinal implants, instruments, biologics, and imaging systems for spine surgery, saw its shares plummet 30.55%. The stock closed at $7.11, down from the prior session's close of $10.23. Markets reacted negatively to the company's first-quarter 2026 earnings release after the bell on May 5, highlighting a revenue shortfall and trimmed guidance for its EOS imaging segment despite core surgical growth.
Earnings Miss and Guidance Adjustment
Alphatec reported Q1 revenue of $192.1 million, up 14% year-over-year but below the $197.5 million consensus estimate. Surgical revenue, the core business, rose 17% to $178 million on 21% higher case volumes and 23% more surgeons, with strength in lateral, ALIF, and cervical procedures. However, EOS imaging revenue fell 18% to $14 million due to fewer system deliveries, dragging overall results.
GAAP EPS came in at -$0.22, wider than the expected -$0.01 loss, though net loss narrowed to $33.9 million from $51.9 million a year ago amid lower litigation costs. Adjusted EBITDA improved to $21 million. Management cited EOS underperformance as short of internal targets and responded by bolstering sales and marketing there.
Full-year guidance was adjusted to $882 million in total revenue (15% growth), with surgical steady at $805 million (17% growth) but EOS cut to $77 million. Adjusted EBITDA outlook held at $134 million, reflecting margin leverage confidence.
Market Context and Trading Activity
Volume exploded to 14 million shares, over five times the 2.66 million average, underscoring intense investor reaction to the earnings. The plunge gapped shares below recent support near $9-10, testing 52-week lows around $6.85-9.11. ATEC underperformed sharply versus peers and sector benchmarks: the iShares U.S. Medical Devices ETF (IHI) dipped just 0.28%, while Health Care Select Sector SPDR ETF (XLV) gained 0.39%. Broader indices advanced, with Nasdaq Composite up 1.03% and S&P 500 up 0.81%, highlighting company-specific bearish sentiment.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform’s top-performing AI-driven trading bots amid current market dynamics. Tickeron deploys hundreds of AI bots across thousands of tickers, employing diverse strategies like trend-following, mean reversion, and momentum on timeframes from intraday to long-term. The curated trending section highlights only those delivering the strongest risk-adjusted returns, win rates, and consistency under prevailing conditions—whether bull, bear, or volatile. Metrics such as Sharpe ratio, maximum drawdown, and profit factor guide selections. Explore these bots to potentially enhance your trading edge; sign up for Tickeron to test them with virtual portfolios or live accounts.
What Comes Next for ATEC
Investors will monitor EOS sales recovery through strengthened sales efforts and Q2 procedure growth. Next earnings are slated for late July, with focus on meeting $882 million full-year revenue and $134 million adjusted EBITDA targets. Analyst consensus remains bullish with price targets averaging around $23-24, though recent cuts like Canaccord’s to $23 reflect EOS concerns. Sector tailwinds in spine surgery innovation persist, but execution risks loom amid high debt and competitive pressures from peers like Globus Medical (GMED). Broader healthcare demand and macroeconomic factors could influence sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
ATEC in +4.17% Uptrend, growing for three consecutive days on June 05, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ATEC advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ATEC's RSI Oscillator exited the oversold zone, of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 09, 2026. You may want to consider a long position or call options on ATEC as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ATEC just turned positive on May 19, 2026. Looking at past instances where ATEC's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
ATEC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATEC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ATEC entered a downward trend on May 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ATEC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ATEC's P/B Ratio (128.205) is very high in comparison to the industry average of (10.947). P/E Ratio (0.000) is within average values for comparable stocks, (63.393). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.718). ATEC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (1.598) is also within normal values, averaging (23.694).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company with interests in medical equipment and supplies
Industry MedicalNursingServices